Skip to main content
Triangle logo TriangleGet started

[177Lu]Lu-DOTATATE (NCT06955169)

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment: a one-minute explainerNCT069551691 min

[177Lu]Lu-DOTATATE trial for Intracranial Meningioma (NCT06955169). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with growing intracranial meningioma after surgery or biopsy and radiation, unsuitable for or declining further local treatment. A qualifying receptor PET scan is required. NF2-related schwannomatosis is excluded.

The idea: compare lutetium-177 dotatate with bevacizumab, everolimus or sunitinib. Dotatate binds somatostatin receptors to deliver radiation to tumor cells. Patients receive four infusions, with two more optional. Control patients may switch after progression. Researchers measure time without progression.

This phase 2 study plans 130 patients. RTOG Foundation sponsors seventeen recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.